ABCL:NASDAQ
AbCellera Biologics Inc
$11.02
arrow_downward
-0.09%(-0.0100) 1D
$11.27
arrow_upward
+2.27% (+0.25)todayPre-market
Closed: Nov 18, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$11.16
High
$11.55
Low
$10.96
Mkt. cap
3.60B
Avg. vol.
3.65M
Volume
5.34K
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.48
Beta
1.59
Shares outstanding
326.62M
No. of employees
562
Open
$11.16
High
$11.55
Low
$10.96
Mkt. cap
3.60B
Avg. vol.
3.65M
Volume
5.34K
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.48
Beta
1.59
Shares outstanding
326.62M
No. of employees
562
News stories
From web sources and news partners
Stocks Down Under
·
16 hours ago
AbCellera Biologics (NDQ:ABCL): The Science Has Been De-Risked, Now Comes The Wait For Commercialisation
Investing.com
·
2 days ago
Jefferies reiterates Buy on AbCellera stock, $21 target on VMS therapy
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth Care
Industry-
Websiteabcellera.com
Analyst ratings
Based on 11 analysts giving stock ratings to ABCL in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ABCL in the last 3 months.
Highest
Current $11.02
$30.00 (+172.23%)
Average
$19.36 (+75.68%)
Lowest
$14.00 (+27.04%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Daniel Brims Lake Street | Buy | Initiated | $19.00 | +72.4% | 11/18/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $20.00 | +81.5% | 11/16/2026 |
Unknown Analyst UBS | Buy | Maintained | $18.00 | +63.3% | 11/12/2026 |
Alice Nettleton UBS | Buy | Maintained | $18.00 | +63.3% | 11/12/2026 |
Debanjana Chatterjee JonesTrading | Buy | Maintained | $25.00 | +126.9% | 11/10/2026 |
Stephen Willey Stifel Nicolaus | Buy | Reiterated | $14.00 | +27% | 11/10/2026 |
Andrea Newkirk Goldman Sachs | Hold | Maintained | $14.00 | +27% | 11/09/2026 |
Steven Seedhouse Cantor Fitzgerald | Buy | Maintained | $20.00 | +81.5% | 11/09/2026 |
Brian Cheng J.P. Morgan | Buy | Maintained | $17.00 | +54.3% | 11/10/2026 |
Evan Seigerman BMO Capital | Buy | Reiterated | $15.00 | +36.1% | 11/10/2026 |
Roger Song Jefferies | Buy | Initiated | $21.00 | +90.6% | 10/30/2026 |
Srikripa Devarakonda Truist Financial | Buy | Reiterated | $30.00 | +172.2% | 09/02/2026 |
Brendan Smith TD Cowen | Buy | Maintained | - | - | 08/05/2026 |
Last report
Nov 9, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.13 / -$0.18
+26.81%beat
arrow_upward
Revenue / Est. (USD)
10.64M / 6.61M
+60.98%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 44.85M | 8.32M | 4.05M | 10.64M |
Cost of goods sold | 50.09M | 46.66M | 45.99M | - |
Cost of revenue | 50.09M | 46.66M | 45.99M | - |
Research and development expenses | - | - | - | 43.54M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 17.22M | 12.33M | 13.85M | 13.61M |
Operating expense | 23.34M | 19.17M | 20.84M | 63.95M |
Total operating expenses | 73.44M | 65.83M | 66.83M | 63.95M |
Operating income | -28.58M | -57.52M | -62.78M | -53.32M |
Other non operating income | 2.16M | 4.34M | 3.85M | 3.64M |
EBT including unusual items | -19.50M | -49.54M | -58.96M | -42.81M |
EBT excluding unusual items | -20.50M | -49.54M | -58.96M | -42.81M |
Income tax expense | -10.55M | -6.37M | -3.54M | -2.05M |
Effective tax rate | 54.13% | 12.86% | 6.00% | 4.80% |
Other operating expenses | - | - | - | - |
Net income | -8.94M | -43.16M | -55.43M | -40.76M |
Net profit margin | -19.94% | -519.12% | -1,368.57% | -383.10% |
Earnings per share | -0.03 | -0.14 | -0.18 | -0.13 |
Interest and investment income | 5.92M | 3.64M | - | 6.87M |
Interest expense | - | - | -42.00K | - |
Net interest expenses | 5.92M | 3.64M | -42.00K | 6.87M |
Depreciation and amortization charges | 6.12M | 6.84M | 6.99M | 6.81M |
EBITDA | -22.46M | -50.68M | -55.79M | -46.51M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events